Clinical Trial

A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)

Name: A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) — clinical trial record (NCT07455045)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.

Trial Details

NCT Number	NCT07455045
Lead Sponsor	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Conditions	High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)
Enrollment	40 participants
Start Date	2026-03-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-06